Aquestive Therapeutics Inc (AQST) Stock Price, Quote & News

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 941 1900

Website: www.aquestive.com

Address:

30 Technology Drive, Warren, United States

DJTEM Jun. 4 at 4:07 PM

$AQST According Goldie school it's a Strong buy. PT 12$

0 · Reply

BigGainTom Jun. 4 at 3:17 PM

$AQST love that 420

0 · Reply

Doccjc62 Jun. 4 at 2:49 PM

$AQST Accumulation going on,,some of it is me,, Great opportunity here.

0 · Reply

WrongWay123 Jun. 4 at 2:44 PM

$AQST told ya.

0 · Reply

prototyper Jun. 4 at 2:39 PM

$AQST market only opened for an hour and volume is 900K. Someones loading up.

0 · Reply

Skinny__ Jun. 4 at 2:28 PM

$AQST it’s quiet in here

0 · Reply

Exeltrader Jun. 4 at 2:20 AM

$AQST Based on the latest Fintel filing data updated through June 3, 2026, big investors are overwhelmingly buying and accumulating AQST, demonstrating a strong bullish shift despite recent price volatility.While the total number of unique institutional owners decreased slightly by 10.14% last quarter to 185 total owners, the actual volume of shares being hoarded by major institutions tells the real story.Major Inflows and Long-Term AccumulationSignificant Share Increase: Institutional shares held in long positions surged to 76,932,240 shares. This represents a massive net increase of 4.09 million shares (+5.61%) compared to the most recent reporting period. The total institutional "long value" sitting in AQST has climbed to $345.6 million.Portfolio Allocation Upswing: Institutional managers aren't just buying shares because the company grew; they are actively dedicating more portfolio space to AQST. The average portfolio allocation dedicated to this specific stock increased by 15.26%.

1 · Reply

BigGainTom Jun. 3 at 8:28 PM

$AQST nice rally

0 · Reply

prototyper Jun. 3 at 8:03 PM

$AQST nice rally

0 · Reply

RunFYLife Jun. 3 at 1:32 PM

$AQST go down baby, then i can load!!!

1 · Reply

Aquestive Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:00 AM EDT - 21 days ago

Aquestive Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:00 AM EDT - 21 days ago

Aquestive Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 21 days ago

Aquestive Therapeutics Slides: Q1 2026

2026-05-13T20:36:49.000Z - 21 days ago

Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

May 13, 2026, 4:01 PM EDT - 21 days ago

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 9:31 AM EDT - 23 days ago

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 6, 2026, 7:00 AM EDT - 4 weeks ago

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Aquestive Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Aquestive Therapeutics Proxy statement: Proxy filing

2026-04-24T11:41:01.000Z - 5 weeks ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

Apr 16, 2026, 9:00 AM EDT - 7 weeks ago

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

2026-04-15T13:51:38.000Z - 7 weeks ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

Apr 9, 2026, 8:23 AM EDT - 2 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

2026-03-30T11:16:34.000Z - 2 months ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

2026-03-20T11:11:07.000Z - 2 months ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

Mar 20, 2026, 7:00 AM EDT - 2 months ago

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Mar 12, 2026, 9:00 AM EDT - 3 months ago

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Mar 10, 2026, 8:25 AM EDT - 3 months ago

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 9, 2026, 4:01 PM EDT - 3 months ago

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 10:40 AM EDT - 3 months ago

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 6, 2026, 2:01 PM EST - 3 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-03-05T18:20:15.000Z - 3 months ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

Mar 5, 2026, 8:00 AM EST - 3 months ago

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Aquestive Therapeutics Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Aquestive Therapeutics Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 3 months ago

Aquestive Therapeutics Slides: Q4 2025

2026-03-04T21:20:27.000Z - 3 months ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

2026-03-04T21:19:36.000Z - 3 months ago

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

Mar 4, 2026, 4:01 PM EST - 3 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 12:00 PM EST - 3 months ago

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 7:00 AM EST - 3 months ago

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Feb 24, 2026, 7:00 AM EST - 3 months ago

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

2026-02-20T12:06:15.000Z - 3 months ago

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

2026-02-18T12:11:06.000Z - 3 months ago

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

2026-02-03T13:46:32.000Z - 4 months ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

2026-02-02T19:05:09.000Z - 4 months ago

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

2026-02-02T15:45:14.000Z - 4 months ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

2026-02-02T15:40:09.000Z - 4 months ago

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

Feb 2, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Transcript: Status update

Feb 2, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Press release: Status update

Feb 2, 2026, 8:00 AM EST - 4 months ago

Aquestive Therapeutics Slides: Status update

2026-02-02T12:12:20.000Z - 4 months ago

Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

Feb 2, 2026, 7:10 AM EST - 4 months ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:00 AM EST - 4 months ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Jan 9, 2026, 7:00 AM EST - 5 months ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Dec 4, 2025, 10:00 AM EST - 6 months ago

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 8:00 AM EST - 7 months ago

Aquestive Therapeutics Slides: Q3 2025

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 8, 2025, 7:00 AM EDT - 8 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Sep 28, 2025, 6:00 PM EDT - 8 months ago

Aquestive Therapeutics Slides: Corporate Presentation

Sep 8, 2025, 10:00 AM EDT - 9 months ago

Aquestive Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 9 months ago

Aquestive Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 14, 2025, 6:28 AM EDT - 10 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aug 14, 2025, 6:00 AM EDT - 10 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Aquestive Therapeutics Slides: Q2 2025

Aug 11, 2025, 4:01 PM EDT - 10 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

DJTEM Jun. 4 at 4:07 PM

$AQST According Goldie school it's a Strong buy. PT 12$

0 · Reply

BigGainTom Jun. 4 at 3:17 PM

$AQST love that 420

0 · Reply

Doccjc62 Jun. 4 at 2:49 PM

$AQST Accumulation going on,,some of it is me,, Great opportunity here.

0 · Reply

WrongWay123 Jun. 4 at 2:44 PM

$AQST told ya.

0 · Reply

prototyper Jun. 4 at 2:39 PM

$AQST market only opened for an hour and volume is 900K. Someones loading up.

0 · Reply

Skinny__ Jun. 4 at 2:28 PM

$AQST it’s quiet in here

0 · Reply

Exeltrader Jun. 4 at 2:20 AM

1 · Reply

BigGainTom Jun. 3 at 8:28 PM

$AQST nice rally

0 · Reply

prototyper Jun. 3 at 8:03 PM

$AQST nice rally

0 · Reply

RunFYLife Jun. 3 at 1:32 PM

$AQST go down baby, then i can load!!!

1 · Reply

drose0527 Jun. 3 at 12:34 PM

$AQST Today marks the first open below $4 since March 2. Next levels to test will be 3.82 than 3.77. We have at a minimum of 3-5 weeks of downwards price pressure as right now time is working against us with no news or anything likely coming from company till the August 10 C.C. So this looks to be in full decomposition from now to early-mid July when the anticipated announcement to hopefully come by August 10th as company will turn page into Q3. Scoop up these cheapies cause I doubt we will ever revisit 3’s again after a double launch in Q1 with Anaphylm and libervant. This will be 10+ easy by end of Q1

1 · Reply

shawn45 Jun. 3 at 12:29 PM

$OTLK Time starts for OTLK with only 57 days left for an US FDA approval. Early Approval chances are so high aswell.. $AQST $NVDA $MU $AMZN 5 Great stocks..

1 · Reply

Mnpois Jun. 3 at 6:26 AM

$AQST 3s love it not surprised

0 · Reply

ClearCities Jun. 2 at 9:55 PM

$AQST 'Cause you're hot then you're cold You're yes then you're no You're in then you're out You're up then you're down You're wrong when it's right It's black and it's white We fight, we break up We kiss, we make up .

4 · Reply

ae1213 Jun. 2 at 7:29 PM

$AQST you kids are a bunch of dreamers. This co still hasn’t secured FDA advisory meeting regarding additional PK and HF studies, doesn’t have promised filings in Canada and Europe. Would they ever be approved? Or is it a subtle way FDA tells them to stick their film where it belongs and go away? I would like to learn …

1 · Reply

DJTEM Jun. 2 at 6:30 PM

$SLS The 80th won't necessarily be announced. Topline results may arrive directly. After a big gain the school is still flat here. U should buy $UWMC and $AQST Goldie

2 · Reply

LazyRobot Jun. 2 at 5:14 PM

$AQST My 3.90 limit orders triggered, now waiting to see if the 3.85's come in.

0 · Reply

astacey Jun. 2 at 5:04 PM

$AQST would've to hear genuine price targets for this company following approval of 109? Is $20 sp pushing It or is that fair value?

4 · Reply

Stone52 Jun. 2 at 4:08 PM

$AQST Nice move, LD!

0 · Reply

omega42 Jun. 2 at 3:21 PM

$AQST when XBI is down 3%, most of bios are down as well. take it as an opportunity to accumulate.

0 · Reply

omega42 Jun. 2 at 3:19 PM

$AQST this is a good accumulation period. in about 1.5months we may know the results of the PK study and confirmation of Q3 resubmission. initially went with 10k shares to 1st PDUFA, currently closer to 90k and much lower entry point sp.

0 · Reply

drose0527 Jun. 2 at 2:30 PM

$AQST @BigGainTom 🤣🤣🤣🤣 looks like 3.88 was a breeze now on to 3.77

0 · Reply

Market Cap	493.02M
Revenue (ttm)	44.55M
Net Income (ttm)	-83.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-188.06%
Debt to Equity Ratio	-0.74

Volume	1,698,400
Avg Vol	1,465,458
Day's Range	N/A - N/A
Shares Out	125.45M
Stochastic %K	14%
Beta	1.46
Analysts	Strong Sell
Price Target	$8.89